Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene

Proc Natl Acad Sci U S A. 1984 Nov;81(22):7194-8. doi: 10.1073/pnas.81.22.7194.

Abstract

Inoculation of rabbits and mice with a vaccinia-rabies glycoprotein recombinant (V-RG) virus resulted in rapid induction of high concentrations of rabies virus-neutralizing antibodies and protection from severe intracerebral challenge with several strains of rabies virus. Protection from virus challenge also was achieved against the rabies-related Duvenhage virus but not against the Mokola virus. Effective immunization by V-RG depended on the expression of a rabies glycoprotein that registered proline rather than leucine as the eighth amino acid from its NH2 terminus (V-RGpro8). A minimum dose required for effective immunization of mice was 10(4) plaque-forming units of V-RGpro8 virus. beta-propiolactone-inactivated preparations of V-RGpro8 virus also induced high levels of rabies virus-neutralizing antibody and protected mice against intracerebral challenge with street rabies virus. V-RGpro8 virus was highly effective in priming mice to generate a secondary rabies virus-specific cytotoxic T-lymphocyte response following culture of lymphocytes with either ERA or PM strains of rabies virus.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • DNA, Recombinant
  • Female
  • Genes, Viral
  • Genetic Vectors
  • Glycoproteins / genetics
  • Glycoproteins / immunology*
  • Immunity, Cellular
  • Immunologic Memory
  • Mice
  • Rabies Vaccines / immunology*
  • Rabies virus / genetics
  • Rabies virus / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccinia virus / genetics
  • Viral Proteins / genetics
  • Viral Proteins / immunology

Substances

  • DNA, Recombinant
  • Glycoproteins
  • Rabies Vaccines
  • Viral Proteins